Comparing Silverback Therapeutics (NASDAQ:SBTX) & AEON Biopharma (NASDAQ:AEON)

Silverback Therapeutics (NASDAQ:SBTX) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Silverback Therapeutics and AEON Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0	0	0	0	0.00
AEON Biopharma	0	1	1	1	3.00

Profitability

This table compares Silverback Therapeutics and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
AEON Biopharma	N/A	N/A	-994.63%

Volatility and Risk

Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Valuation & Earnings

This table compares Silverback Therapeutics and AEON Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-4.14
AEON Biopharma	N/A	N/A	-$36.63 million	$5.04	0.21

Silverback Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

AEON Biopharma beats Silverback Therapeutics on 8 of the 11 factors compared between the two stocks.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.